The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
Open Access
- 27 May 2023
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 12 (6) , 971
Abstract
Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to evaluate how fosfomycin was used in patients admitted to the Polyclinic of Palermo between January 2017 and July 2022. Clinical indications, therapeutic associations, clinical outcomes, and any side effects were analyzed. Intravenous fosfomycin was used in 343 patients, 63% male, with a mean age of 68 years (range 15–95). Urinary tract infections (UTIs) and hospital-acquired pneumonia (HAP) were the main indications for treatment (19% and 18% of the total cases, respectively), followed by skin and soft tissue infections and sepsis. IV fosfomycin was administered in combination with other antibacterial agents, the most common of which were ceftazidime/avibactam (35%), meropenem (17%), and colistin (14%). Nineteen patients received it as monotherapy for UTIs. About 66% had resolution of the infectious process with clinical remission (cure or discharge). Electrolyte disturbances occurred in 2.6% and gastrointestinal symptoms occurred in 2.9%. The data showed that IV fosfomycin is a safe and effective therapeutic option in the treatment of infections with multidrug-resistant microorganisms.Keywords
Funding Information
- VQR improvement assigned to the Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties of the University of Palermo
This publication has 35 references indexed in Scilit:
- Fosfomycin Susceptibility in Carbapenem-Resistant Enterobacteriaceae from GermanyJournal of Clinical Microbiology, 2014
- Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteriaInternational Journal of Antimicrobial Agents, 2014
- Alternatives to carbapenems in ESBL-producing Escherichia coli infectionsMedecine Et Maladies Infectieuses, 2013
- Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challengeClinical Microbiology and Infection, 2013
- Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycinInternational Journal of Antimicrobial Agents, 2012
- Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteriaScandinavian Journal of Infectious Diseases, 2011
- Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycinInternational Journal of Antimicrobial Agents, 2010
- Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluationClinical Microbiology and Infection, 2010
- Susceptibility of Urinary Tract Bacteria to FosfomycinAntimicrobial Agents and Chemotherapy, 2009
- Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studiesInternational Journal of Antimicrobial Agents, 2009